Network dysfunction in α‐synuclein transgenic mice and human Lewy body dementia

Dementia with Lewy bodies (DLB) is associated with the accumulation of wild‐type human α‐synuclein (SYN) in neurons and with prominent slowing of brain oscillations on electroencephalography (EEG). However, it remains uncertain whether the EEG abnormalities are actually caused by SYN.

[1]  M. Chesselet,et al.  Sleep Dysfunction and EEG Alterations in Mice Overexpressing Alpha-Synuclein , 2018, Journal of Parkinson's disease.

[2]  L. Mucke,et al.  Tau Reduction Prevents Disease in a Mouse Model of Dravet Syndrome , 2014, Annals of neurology.

[3]  F. Gage,et al.  Accumulation of oligomer-prone α-synuclein exacerbates synaptic and neuronal degeneration in vivo. , 2014, Brain : a journal of neurology.

[4]  R. Edwards,et al.  The Function of α-Synuclein , 2013, Neuron.

[5]  Heidi E Kirsch,et al.  Seizures and epileptiform activity in the early stages of Alzheimer disease. , 2013, JAMA neurology.

[6]  Christine Guo,et al.  Rivastigmine is associated with restoration of left frontal brain activity in Parkinson's disease , 2013, Movement disorders : official journal of the Movement Disorder Society.

[7]  D. Holtzman,et al.  Antisense Reduction of Tau in Adult Mice Protects against Seizures , 2013, The Journal of Neuroscience.

[8]  S. Sisodiya,et al.  A comparative study of the dentate gyrus in hippocampal sclerosis in epilepsy and dementia , 2013, Neuropathology and applied neurobiology.

[9]  S. Younkin,et al.  Tau Loss Attenuates Neuronal Network Hyperexcitability in Mouse and Drosophila Genetic Models of Epilepsy , 2013, The Journal of Neuroscience.

[10]  György Buzsáki,et al.  Striatal GABAergic and cortical glutamatergic neurons mediate contrasting effects of cannabinoids on cortical network synchrony , 2012, Proceedings of the National Academy of Sciences.

[11]  Keith A. Vossel,et al.  Levetiracetam suppresses neuronal network dysfunction and reverses synaptic and cognitive deficits in an Alzheimer’s disease model , 2012, Proceedings of the National Academy of Sciences.

[12]  Amy L. Shelton,et al.  Reduction of Hippocampal Hyperactivity Improves Cognition in Amnestic Mild Cognitive Impairment , 2012, Neuron.

[13]  Edward O. Mann,et al.  Inhibitory Interneuron Deficit Links Altered Network Activity and Cognitive Dysfunction in Alzheimer Model , 2012, Cell.

[14]  M. Chesselet,et al.  Cognitive deficits in a mouse model of pre‐manifest Parkinson’s disease , 2012, The European journal of neuroscience.

[15]  M. Chesselet,et al.  A Progressive Mouse Model of Parkinson’s Disease: The Thy1-aSyn (“Line 61”) Mice , 2012, Neurotherapeutics.

[16]  C. Adler,et al.  Parkinson's disease, cortical dysfunction, and alpha‐synuclein , 2011, Movement disorders : official journal of the Movement Disorder Society.

[17]  L. Mucke,et al.  Amyloid-β/Fyn–Induced Synaptic, Network, and Cognitive Impairments Depend on Tau Levels in Multiple Mouse Models of Alzheimer's Disease , 2011, The Journal of Neuroscience.

[18]  Carla Cordivari,et al.  Myoclonic disorders: a practical approach for diagnosis and treatment , 2011, Therapeutic advances in neurological disorders.

[19]  Jürgen Götz,et al.  Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models , 2010, Cell.

[20]  Carolyn A. Coughlan,et al.  Effects of donepezil on amyloid-β and synapse density in the Tg2576 mouse model of Alzheimer's disease , 2009, Brain Research.

[21]  E. Londos,et al.  Electroencephalogram Variability in Dementia with Lewy Bodies, Alzheimer’s Disease and Controls , 2008, Dementia and Geriatric Cognitive Disorders.

[22]  M. Onofrj,et al.  EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. , 2008, Brain : a journal of neurology.

[23]  Anatol C. Kreitzer,et al.  Aberrant Excitatory Neuronal Activity and Compensatory Remodeling of Inhibitory Hippocampal Circuits in Mouse Models of Alzheimer's Disease , 2007, Neuron.

[24]  L. Mucke,et al.  Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.

[25]  M. Sperling,et al.  Interictal EEG and the Diagnosis of Epilepsy , 2006, Epilepsia.

[26]  S Minoshima,et al.  Diagnosis and management of dementia with Lewy bodies , 2005, Neurology.

[27]  C. Elger,et al.  Response: Definitions Proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE) , 2005 .

[28]  C. Elger,et al.  Epileptic Seizures and Epilepsy: Definitions Proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE) , 2005, Epilepsia.

[29]  S. Brassen,et al.  Prediction of treatment response to rivastigmine in Alzheimer’s dementia , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[30]  K. Jellinger.  Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies , 2004, Neurology.

[31]  E. Bigio,et al.  Can Alzheimer’s Disease and Dementias with Lewy Bodies be Distinguished Clinically? , 2003, Journal of geriatric psychiatry and neurology.

[32]  Jacob Raber,et al.  Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[33]  C. Adler,et al.  Electrophysiology of the myoclonus in dementia with Lewy bodies , 2003, Neurology.

[34]  J. Knottnerus,et al.  Systematic Review and Meta‐analysis of Incidence Studies of Epilepsy and Unprovoked Seizures , 2002, Epilepsia.

[35]  C. Adler,et al.  Small‐Amplitude cortical myoclonus in Parkinson's disease: Physiology and clinical observations , 2002, Movement disorders : official journal of the Movement Disorder Society.

[36]  Makoto Hashimoto,et al.  Differential neuropathological alterations in transgenic mice expressing α‐synuclein from the platelet‐derived growth factor and Thy‐1 promoters , 2002, Journal of neuroscience research.

[37]  S. Fahn,et al.  A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus , 2001, Neurology.

[38]  Makoto Hashimoto,et al.  β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[39]  M. Vitek,et al.  Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice. , 2001, Journal of cell science.

[40]  Vladimir Hachinski,et al.  Clinical and Pathologic Features of Two Groups of Patients With Dementia With Lewy Bodies: Effect of Coexisting Alzheimer-Type Lesion Load , 2001, Alzheimer disease and associated disorders.

[41]  V. Jelic,et al.  Responder Characteristics to a Single Oral Dose of Cholinesterase Inhibitor: A Double-Blind Placebo-Controlled Study withTacrine in Alzheimer P atients , 2000, Dementia and Geriatric Cognitive Disorders.

[42]  I. McKeith,et al.  Spectrum of Parkinson's disease, Parkinson's dementia, and Lewy body dementia. , 2000, Neurologic clinics.

[43]  R. Hamilton,et al.  Lewy Bodies in Alzheimer's Disease: A Neuropathological Review of 145 Cases Using α‐Synuclein Immunohistochemistry , 2000, Brain pathology.

[44]  Kang Hu,et al.  High-Level Neuronal Expression of Aβ1–42 in Wild-Type Human Amyloid Protein Precursor Transgenic Mice: Synaptotoxicity without Plaque Formation , 2000, The Journal of Neuroscience.

[45]  V. Gribkoff,et al.  Cognition-enhancing drugs increase stimulated hippocampal theta rhythm amplitude in the urethane-anesthetized rat. , 1999, The Journal of pharmacology and experimental therapeutics.

[46]  D. Maraganore,et al.  The incidence and prevalence of myoclonus in Olmsted County, Minnesota. , 1999, Mayo Clinic proceedings.

[47]  I G McKeith,et al.  EEG findings in dementia with Lewy bodies and Alzheimer’s disease , 1999, Journal of neurology, neurosurgery, and psychiatry.

[48]  J. Trojanowski,et al.  Editorial on Consensus Recommendations for the Postmortem Diagnosis of Alzheimer Disease from the National Institute on Aging and the Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer Disease , 1997, Journal of neuropathology and experimental neurology.

[49]  John Q. Trojanowski,et al.  Consensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease , 1997, Neurobiology of Aging.

[50]  S. Fahn,et al.  Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse lewy body disease and 34 pathologically confirmed cases of parkinson's disease , 1997, Neurology.

[51]  T. Freund,et al.  Loss of Calbindin-D28K immunoreactivity from dentate granule cells in human temporal lobe epilepsy , 1997, Neuroscience.

[52]  H. Shibasaki,et al.  Clinical trial of piracetam in patients with myoclonus: Nationwide multiinstitution study in Japan , 1996, Movement disorders : official journal of the Movement Disorder Society.

[53]  L Forsgren,et al.  Incidence and Clinical Characterization of Unprovoked Seizures in Adults: A Prospective Population‐Based Study , 1996, Epilepsia.

[54]  R. Miettinen,et al.  Loss of cholinergic neurons in the nucleus basalis induces neocortical electroencephalographic and passive avoidance deficits , 1992, Neuroscience.

[55]  E. Nestler,et al.  Chronic Electroconvulsive Seizures Down–Regulate Expression of the Immediate‐Early Genes c‐fos and c‐jun in Rat Cerebral Cortex , 1990, Journal of neurochemistry.

[56]  G. Sperk,et al.  Neuropeptide Y biosynthesis is markedly induced in mossy fibers during temporal lobe epilepsy of the rat , 1990, Neuroscience Letters.

[57]  G. Buzsáki,et al.  Nucleus basalis and thalamic control of neocortical activity in the freely moving rat , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[58]  Sander Greenland,et al.  Modern Epidemiology 3rd edition , 1986 .

[59]  J. Miller,et al.  Biochemical and immunohistochemical correlates of kindling-induced epilepsy: role of calcium binding protein , 1983, Brain Research.

[60]  Erik D Roberson,et al.  Quantifying biomarkers of cognitive dysfunction and neuronal network hyperexcitability in mouse models of Alzheimer's disease: depletion of calcium-dependent proteins and inhibitory hippocampal remodeling. , 2011, Methods in molecular biology.

[61]  E. Perry,et al.  Dementia with Lewy bodies: choline acetyltransferase parallels nucleus basalis pathology , 1999, Journal of Neural Transmission.

[62]  E. Perry,et al.  Cholinergic Transmitter and Neurotrophic Activities in Lewy Body Dementia: Similarity to Parkinson's and Distinction from Alzheimer Disease , 1993, Alzheimer disease and associated disorders.

[63]  P. Thompson,et al.  Effectiveness of piracetam in cortical myoclonus , 1993, Movement disorders : official journal of the Movement Disorder Society.

[64]  M. Graffar.  [Modern epidemiology]. , 1971, Bruxelles medical.